Skip to search formSkip to main contentSkip to account menu

OPC 13013

Known as: OPC-13013 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

cilostazol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Effects of cilostazol (OPC-13013, CAS 73963-72-1), a selective inhibitor of platelet cAMP-phosphodiesterase, on peripheral… 
1989
1989
Effects of cilostazol on platelet function.
The antiplatelet effect of cilostazol (OPC-13013) was investigated by means of both in vitro and in vivo examinations. With the… 
1986
1986
Effect of cilostazol on experimental cerebral infarction in rabbits.
The effects of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1H)-quinolinone (cilostazol, OPC-13013… 
1985
1985
Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors, IV. Synthesis and biological activity of the metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl)butoxy]-2-oxo-1,2,3,4…
The metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl) butoxy]-2-oxo-1, 2, 3, 4-tetrahydroquinoline (OPC-13013) (1), which has a… 
1985
1985
General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.
The pharmacological effects of the new antithrombotic drug, cilostazol (6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2… 
1985
1985
Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.
A new antithrombotic drug, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013… 
1985
1985
The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.
The metabolism of cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013) was studied… 
1985
1985
Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion.
Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) was evaluated experimentally… 
1985
1985
Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction.
The effect of the oral administration of a new vasodilator, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro… 
1985
1985
Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.
Acute arterial obstruction in hind limb was experimentally induced by intra-arterial injection of sodium laurate saline solution… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)